Day One Biopharmaceuticals Inc
NASDAQ:DAWN
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
11.58
17.69
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one DAWN stock under the Base Case scenario is 18.62 USD. Compared to the current market price of 13.54 USD, Day One Biopharmaceuticals Inc is Undervalued by 27%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Day One Biopharmaceuticals Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for DAWN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Day One Biopharmaceuticals Inc
Balance Sheet Decomposition
Day One Biopharmaceuticals Inc
Current Assets | 581m |
Cash & Short-Term Investments | 558.4m |
Receivables | 8.7m |
Other Current Assets | 13.9m |
Non-Current Assets | 19.8m |
Long-Term Investments | 117k |
PP&E | 3.5m |
Intangibles | 16.2m |
Current Liabilities | 39.7m |
Accounts Payable | 3m |
Accrued Liabilities | 30.8m |
Other Current Liabilities | 6m |
Non-Current Liabilities | 5.6m |
Other Non-Current Liabilities | 5.6m |
Earnings Waterfall
Day One Biopharmaceuticals Inc
Revenue
|
102m
USD
|
Cost of Revenue
|
-2.3m
USD
|
Gross Profit
|
99.7m
USD
|
Operating Expenses
|
-311.1m
USD
|
Operating Income
|
-211.5m
USD
|
Other Expenses
|
127.2m
USD
|
Net Income
|
-84.3m
USD
|
Free Cash Flow Analysis
Day One Biopharmaceuticals Inc
USD | |
Free Cash Flow | USD |
DAWN Profitability Score
Profitability Due Diligence
Day One Biopharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Day One Biopharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
DAWN Solvency Score
Solvency Due Diligence
Day One Biopharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Day One Biopharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DAWN Price Targets Summary
Day One Biopharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for DAWN is 37.74 USD with a low forecast of 28.28 USD and a high forecast of 50.4 USD.
Dividends
Current shareholder yield for DAWN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
DAWN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Day One Biopharmaceuticals, Inc. operates as a holding company. The company is headquartered in South San Francisco, California and currently employs 42 full-time employees. The company went IPO on 2021-05-27. The company is focused on developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers. The company seeks to identify, acquires, and develops product candidates that target high-value oncogenic drivers in cancers with unmet need, with an initial focus on pediatric patients. Its lead product candidate, DAY101 (tovorafenib), is an oral, brain-penetrant, highly selective type II pan-rapidly accelerated fibrosarcoma (pan-RAF), kinase inhibitor. Tovorafenib is also used for the treatment of low-grade gliomas (LGGs). Its second product candidate, pimasertib, is an oral, highly selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK), a key signaling node in the MAPK pathway. The company has initiated a phase II trial of tovorafenib for pediatric patients with relapsed or progressive low-grade glioma (pLGG), the common brain tumor diagnosed in children.
Contact
IPO
Employees
Officers
The intrinsic value of one DAWN stock under the Base Case scenario is 18.62 USD.
Compared to the current market price of 13.54 USD, Day One Biopharmaceuticals Inc is Undervalued by 27%.